{
  "title": "Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab.",
  "pmid": "40579407",
  "doi": null,
  "affiliations": [
    "Department of Medical Oncology, Institut Bergonié, Bordeaux, France.",
    "Explicyte, Bordeaux, France.",
    "Department of Medical Oncology, Institut Bergonié, Bordeaux, France.",
    "Department of Medicine, Oncopole, Toulouse, France.",
    "DITEP, Gustave Roussy, Paris, France.",
    "Department of Medical Oncology, Institut Bergonié, Bordeaux, France.",
    "Explicyte, Bordeaux, France.",
    "Department of Medical Imaging, Institut Bergonié, Bordeaux, France.",
    "Inserm U1219, Bordeaux Population Health Research Center, EPICENE team, University of Bordeaux, Bordeaux, France.",
    "Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.",
    "Inserm U1219, Bordeaux Population Health Research Center, EPICENE team, University of Bordeaux, Bordeaux, France.",
    "Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.",
    "Department of Pathology, Institut Bergonié, Bordeaux, France.",
    "Explicyte, Bordeaux, France.",
    "Department of Medical Oncology, Institut Bergonié, Bordeaux, France. a.italiano@bordeaux.unicancer.fr.",
    "Faculty of Medicine, University of Bordeaux, Bordeaux, France. a.italiano@bordeaux.unicancer.fr."
  ]
}